ABOUT US

MC2 Therapeutics is a privately held dermatology innovation company that develops science-based topical solutions across prescription medicines and advanced DermoCosmetics.  At the core of our innovation is proprietary PAD technology™, a breakthrough formulation platform that is designed to overcome the traditional trade-offs of topical product development—enabling MC2 to optimise efficacy, deep deposition, stability, tolerability, and elegant user experience together, without compromise.

MC2 launched its first PAD technology™-based commercial pharmaceutical product, Wynzora® Cream, for the treatment of plaque psoriasis in the United States in 2021. Wynzora® Cream is partnered with leading pharmaceutical companies specialising in dermatology across multiple markets and is launched in Europe, US, Australia, and Canada improving the lives of more than one million patients worldwide every day. Read more about psoriasis and Wynzora® Cream here.

Building on our dermatology expertise and proprietary PAD technology™, MC2 develops advanced DermoCosmetic products, including cosmetics and medical devices, for people living with itchy, dry, and sensitive skin. Our DermoCosmetic portfolio comprises three products: Chronic Itch, Intimate Itch, and Dry Skin. Performance is proven in randomised clinical trials across multiple representative populations including chronic kidney disease associated pruritus, vulvar lichen sclerosis and atopic dermatitis. We are committed to DermoCosmetics and further portfolio expansions are ongoing at our internal state-of-the-art formulation laboratory. Read more about our DermoCosmetic pipeline here.

MC2 Therapeutics is headquartered in Hørsholm, Denmark and in Guildford, United Kingdom where the MC2 formulation laboratory is located.

Our team and operating model

MC2 Therapeutics is an experienced, multidisciplinary dermatology company with expertise across commercial strategy, pharmaceutical development, topical formulation science, clinical dermatology, regulatory and quality management, global supply, and international partnering.

Our operating model is defined by focused excellence: developing differentiated topical products; protecting the science and intellectual property behind them; ensuring reliable global supply through a qualified CMO network; and enabling strong partners to build successful dermatology franchises.

We work selectively with partners that have strong medical orientation, high-quality commercial organisations, established market access, and a clear commitment to dermatology—partners that are well placed to bring our innovations to patients and consumers.

Partnership is not simply a route to market; it is integral to how we operate. We believe that the success of our partners—and the satisfaction and wellbeing of the people we serve together—is the true measure of success.